Progenitec envisions the creation of innovative wound diagnosis technologies. We have secured over US $3 million in external funding from the National Institute of Health over the past 5 years and assembled a competent team of scientists, clinicians and expert consultants with distinguished experience in clinical studies, manufacturing, intellectual property, and regulatory to ensure the success of new product launches.
What We Do
Progenitec’s innovative technology marks a paradigm shift in wound assessment by detecting biomolecules on wound dressings without directly contacting the patients. The company is developing systems to detect non-healing and infected wounds and is currently in the process of getting FDA clearances and working with reimbursement consultants on two such devices - DETEC® pH and DETEC® Esterase, to monitor wound pH (a biomarker for non-healing wounds) and esterase activity (a biomarker for infection) respectively, by testing discarded wound dressings. These devices provide a more objective and efficient method to diagnose non-healing/infected wounds and better inform the doctors’ decision-making process than current time-consuming diagnostic tests. US and international patents are currently pending.
"The best way to predict the future is to create it"